Alzahrani Talal, Nuqali Abdulelah, Naser Nejat, Jariwala Amar R
Department of Medicine, The George Washington University, Washington, District of Columbia, USA.
Department of Pathology, The George Washington University, Washington, District of Columbia, USA.
BMJ Case Rep. 2019 Feb 3;12(2):bcr-2018-225680. doi: 10.1136/bcr-2018-225680.
We present a patient with Crohn's disease under treatment with adalimumab who developed acute myeloid leukaemia (AML) with core-binding factor beta gene rearrangement. This case report emphasises the importance of long-term close follow-up of patients receiving adalimumab because of the increased risk of developing AML and other malignancies.
我们报告一名正在接受阿达木单抗治疗的克罗恩病患者，该患者发生了伴有核心结合因子β基因重排的急性髓系白血病（AML）。本病例报告强调了对接受阿达木单抗治疗的患者进行长期密切随访的重要性，因为发生AML和其他恶性肿瘤的风险增加。
